Patents by Inventor Melissa S. Egbertson

Melissa S. Egbertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibrinogen receptor antagonists
    Patent number: 5648368
    Abstract: Novel fibrinogen receptor antagonists of the formula:X--Y--Z--Aryl--A--Bare provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, Laura M. Vassallo, George D. Hartman, Wasyl Halczenko, David B. Whitman, James J. Perkins, Amy E. Krause, Nathan Ihle, David Alan Claremon, William Hoffman, Mark E. Duggan
  • Fibrinogen receptor antagonists
    Patent number: 5559127
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## wherein A,B,D,E,Y are as defined in the specification, are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 24, 1996
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, John D. Prugh, Melissa S. Egbertson, Mark E. Duggan, William Hoffman, Wasyl Halezenko, Ben Askew
  • Fibrinogen receptor antagonists
    Patent number: 5525617
    Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2##
    Type: Grant
    Filed: August 24, 1994
    Date of Patent: June 11, 1996
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Melissa S. Egbertson, Laura Birchenough, Laura Vassallo
  • Fibrinogen receptor antagonists
    Patent number: 5494921
    Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2##
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: February 27, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, George D. Hartman, Laura A. Birchenough
  • Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
    Patent number: 5455243
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## such as ##STR2## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: October 3, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Nathan Ihle, George D. Hartman, Laura M. Turchi, William F. Hoffman
  • Fibrinogen receptor antagonists
    Patent number: 5294616
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: March 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, Laura M. Turchi, William L. Laswell
  • Novel sulfonamide fibrinogen receptor antagonists
    Patent number: 5292756
    Abstract: A series of non-peptide derivatives of the formula ##STR1## that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: March 8, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman
  • Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
    Patent number: 5281585
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Nathan Ihle, George D. Hartman, Laura M. Turchi, William F. Hoffman
  • Fibrinogen receptor antagonists
    Patent number: 5264420
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: November 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Nathan Ihle, George D. Hartman, Laura M. Turchi, David Whitman
  • Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
    Patent number: 5217994
    Abstract: Compounds of the general formula ##STR1## and the pharmaceutically acceptable salts thereof whereinn is an integer of from 0 to 6;Y is CH.sub.2, O, SO.sub.2, --CONH--, --NHCO--, or ##STR2## R.sup.1 and R.sup.2 are independently hydrogen,C.sub.1-8 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,amino C.sub.1-4 alkyl,C.sub.1-4 alkylamino C.sub.1-4 alkyl, orC.sub.3-8 cycloalkylwherein R.sup.1 and R.sup.2 may be unsubstituted or substituted with one or more groups chosen from R.sup.3, whereR.sup.3 ishydrogen,C.sub.1-6 alkyl,hydroxy C.sub.0-4 alkyl,carboxy C.sub.0-4 alkyl,C.sub.1-4 alkyloxy C.sub.0-4 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,halogen, orCF.sub.3 ;R.sup.4 isC.sub.1-6 alkyl,heterocyclyl C.sub.0-4 alkyl, oraryl C.sub.0-4 alkyl;R.sup.5 ishydrogen,C.sub.1-6 alkyl,aryl C.sub.0-3 alkyl, orC.sub.1-6 alkylcarbonyloxymethylare used in a method of treating osteoporosis by inhibiting the bone resorption activity of osteoclasts.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: June 8, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, Robert J. Gould, George D. Hartman
  • Method of inhibiting osteoclast-mediated bone resorption by administration of N-heterocyclicalkyl-substituted phenyl derivatives
    Patent number: 5204350
    Abstract: Compounds of the general formula ##STR1## Y is an integer of from 0 to 6 is chosen from: O,SO.sub.2,--CONH--,--NHCO--,--CH2-- or ##STR2## R.sup.1 is substituted or unsubstituted mono- or polycyclic saturated hetero-cyclic ring system having 1, 2 or 3 heteroatoms where said heteroatoms are independently chosen from N, O and S and said substituents are chosen from the group comprising R.sup.2 ;R.sup.2 isC.sub.1-6 alkyl,aryl C.sub.0-6 alkyl,hydroxy C.sub.0-6 alkyl,C.sub.1-6 alkoxy C.sub.0-6 alkyl,carboxy C.sub.0-6 alkyloxo,halogen,CF.sub.3,C.sub.0-4 alkylamino-C.sub.0-6 alkyl orC.sub.0-4 dialkylamino-C.sub.0-6 alkyl;R.sup.3 isC.sub.1-8 alkyl or cycloalkyl,aryl C.sub.0-4 alkyl,hydroxy C.sub.0-4 alkylC.sub.1-4 alkyloxy C.sub.0-4 alkyl,carboxy C.sub.0-4 alkyl,halogen,CF.sub.3 orhydrogen;R.sup.4 ishydrogen,C.sub.1-6 alkyl,aryl C.sub.0-4 alkyl orC.sub.1-6 alkylcarbonyloxymethyl; andR.sup.5 isC.sub.1-6 alkyl,aryl C.sub.0-4 alkyl orheterocycly C.sub.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, George D. Hartman, Robert J. Gould